Antimicrobial Resistance Profile of
Antimicrobial susceptibility profile
Debre Tabor
Pseudomonas aeruginosa
Journal
Ethiopian journal of health sciences
ISSN: 2413-7170
Titre abrégé: Ethiop J Health Sci
Pays: Ethiopia
ID NLM: 101224773
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
20
10
2022
accepted:
16
01
2023
medline:
15
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and the most common antimicrobial-resistant pathogens. It is associated with a variety of infections. This study aimed to determine the prevalence of P. aeruginosa and its antimicrobial resistance profile from different clinical specimens at Debre Tabor Comprehensive Referral Hospital (DTCRH). A cross-sectional study was conducted from May to July 2022 at DTCRH. Socio-demographic and clinical data were collected using a structured questionnaire. Clinical samples (blood, wound swab, urine, and sputum) were collected from 348 study participants and processed following the standard bacteriological techniques. Antibiotic susceptibility testing was done by the Kirby-Bauer disc diffusion method. Data were entered and analyzed using SPSS version 25 statistical software. Descriptive statistics was used to present the findings of the study. The prevalence of P.aeruginosa was 74(19.3%). The detection of the isolates was different based on the type of samples that ranged from 0% to 54.5% from sputum and wound swabs, respectively. P.aeruginosa showed resistance against gentamicin at 62.2%, ceftazidime 51.4%, cefepime 50%, amikacin 29.7%, imipenem 28.4% and ciprofloxacin 14.9%. The level of multi-drug resistance (MDR) was 45.9%, and the suspicious extreme-drug resistance (XDR) rate was 9.5%. Being inpatient and wound swab samples were factors associated with the detection of P.aeruginosa from clinical samples. The antibiotic resistance profile of P. aeruginosa isolates in the present study area was found to be alarming. Actions to minimize the effect of antimicrobial resistance should be strengthened, and further large-scale study should be conducted to find out the main reasons behind antibiotic resistance of P.aeruginosa and other clinically relevant isolates.
Sections du résumé
Background
UNASSIGNED
Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and the most common antimicrobial-resistant pathogens. It is associated with a variety of infections. This study aimed to determine the prevalence of P. aeruginosa and its antimicrobial resistance profile from different clinical specimens at Debre Tabor Comprehensive Referral Hospital (DTCRH).
Methods
UNASSIGNED
A cross-sectional study was conducted from May to July 2022 at DTCRH. Socio-demographic and clinical data were collected using a structured questionnaire. Clinical samples (blood, wound swab, urine, and sputum) were collected from 348 study participants and processed following the standard bacteriological techniques. Antibiotic susceptibility testing was done by the Kirby-Bauer disc diffusion method. Data were entered and analyzed using SPSS version 25 statistical software. Descriptive statistics was used to present the findings of the study.
Results
UNASSIGNED
The prevalence of P.aeruginosa was 74(19.3%). The detection of the isolates was different based on the type of samples that ranged from 0% to 54.5% from sputum and wound swabs, respectively. P.aeruginosa showed resistance against gentamicin at 62.2%, ceftazidime 51.4%, cefepime 50%, amikacin 29.7%, imipenem 28.4% and ciprofloxacin 14.9%. The level of multi-drug resistance (MDR) was 45.9%, and the suspicious extreme-drug resistance (XDR) rate was 9.5%. Being inpatient and wound swab samples were factors associated with the detection of P.aeruginosa from clinical samples.
Conclusion
UNASSIGNED
The antibiotic resistance profile of P. aeruginosa isolates in the present study area was found to be alarming. Actions to minimize the effect of antimicrobial resistance should be strengthened, and further large-scale study should be conducted to find out the main reasons behind antibiotic resistance of P.aeruginosa and other clinically relevant isolates.
Identifiants
pubmed: 37576170
doi: 10.4314/ejhs.v33i3.5
pii: jEJHS.v33.i3.pg423
pmc: PMC10416326
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-432Informations de copyright
© 2023 Tsigereda Asminew, et al.
Références
Sci Rep. 2021 Oct 5;11(1):19710
pubmed: 34611232
Pak J Med Sci. 2014 Sep;30(5):951-4
pubmed: 25225505
Int J Microbiol. 2020 Nov 03;2020:9461901
pubmed: 33204275
BMC Res Notes. 2018 Nov 12;11(1):806
pubmed: 30419962
Pathog Dis. 2014 Jun;71(1):1-19
pubmed: 24737619
Ann Saudi Med. 2016 Jan-Feb;36(1):23-8
pubmed: 26922684
PLoS One. 2021 Nov 15;16(11):e0257272
pubmed: 34780494
Antibiotics (Basel). 2021 Jan 04;10(1):
pubmed: 33406652
Drugs. 2007;67(3):351-68
pubmed: 17335295
Eur Respir J. 2018 Aug 9;52(2):
pubmed: 29976651
Rev Panam Salud Publica. 2020 Sep 23;44:e30
pubmed: 32973892
Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4
pubmed: 20086165
Infect Dis (Auckl). 2019 Nov 05;12:1178633719884951
pubmed: 31723320
Ethiop J Health Sci. 2021 May;31(3):635-644
pubmed: 34483621
BMC Res Notes. 2015 Sep 28;8:488
pubmed: 26416559
Int J Infect Dis. 2016 Aug;49:119-28
pubmed: 27329135
Microb Drug Resist. 2009 Mar;15(1):37-9
pubmed: 19265477
J Antimicrob Chemother. 2007 Nov;60(5):1010-7
pubmed: 17906321
Biomed Res Int. 2018 Jun 11;2018:8060178
pubmed: 29992165
Clin Infect Dis. 2003 Sep 15;37(6):745-51
pubmed: 12955633
Ethiop J Health Sci. 2012 Mar;22(1):7-18
pubmed: 22984327
J Clin Microbiol. 2009 Dec;47(12):4096-101
pubmed: 19828746